Drugs that contain Remdesivir

1. List of Veklury drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(6 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(8 years from now)

US11492353 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Dec, 2031

(8 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US11382926 GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Sep, 2036

(13 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025

NCE-1 date: October, 2024

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic